Thus, SET is one of the important regulators of this leukemogenic mediator and taken together, these observations supports the hypothesis that SET-NUP214 AML is also associated with adverse prognosis due to interactions between the fusion protein and SETBP1/PP2A. The gene discussed is SETBP1; the disease is acute myeloid leukemia.